Page 4 - CIMA SCS Workbook November 2018 - Day 1 Suggested Solutions

CIMA NOVEMBER 2018 – STRATEGIC CASE STUDY

 Greater awareness of what leads to ill health could lead to less reliance on drugs

 Pressure on pharma companies to make drugs more affordable in less developed countries

Technological

 Advances in technology open up new areas of healthcare e.g. stem cell research

 Earlier diagnosis possible e.g. new Apple Watch features low/high heart rate notifications

 Use of Big Data to improve understanding of disease pathways should result in more
effective cures

 Use of Artificial Intelligence (AI) to detect diseases such as cancer more accurately and in
their early stages

Environmental

 Concerns at drug pollution of water systems around the world e.g. due to waste in the
manufacturing process, or drugs being disposed of down lavatories by consumers

 Emergence of new “superbugs” which are resistant to conventional drugs

 Industry in general consumes a lot of energy – manufacturing/distribution/storage of
finished goods

Legal

 High litigation levels in the industry e.g. Johnson & Johnson ordered to pay $4.7 billion in
damages in July 2018 over claims talcum powder led to ovarian cancer

 Need to satisfy regulatory bodies such as NICE/PTA/PRA

 Importance of global patent protection for new drugs

44 KAPLAN PUBLISHING